Kinome-wide activity modeling from diverse public high-quality data sets

Journal of Chemical Information and Modeling

Volumn 53, Issue 1, 2013, Pages 27-38

  Schürer, Stephan C ^a   Muskal, Steven M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Eidogen Sertanty Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; KNOWLEDGE BASED SYSTEMS; MOLECULES; REGRESSION ANALYSIS;

ACTIVITY MODELING; EXPERIMENTAL PROCEDURE; HETEROGENEOUS DATA; HIGH QUALITY DATA; INTEGRATED NETWORKS; QUANTITATIVE MODELS; SMALL MOLECULE INHIBITOR; STRUCTURE ACTIVITY;

CLASSIFICATION (OF INFORMATION);

PROTEIN KINASE;

ARTICLE; ARTIFICIAL INTELLIGENCE; GENETICS; GENOMICS; HUMAN; HUMAN GENOME; METABOLISM; PROTEIN DATABASE; REGRESSION ANALYSIS; STATISTICAL MODEL;

ARTIFICIAL INTELLIGENCE; DATABASES, PROTEIN; GENOME, HUMAN; GENOMICS; HUMANS; MODELS, STATISTICAL; PROTEIN KINASES; REGRESSION ANALYSIS;

MLCS; MLOWN;

EID: 84873024709     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci300403k     Document Type: Article

References (35)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
2. Akritopoulou-Zanze, I.; Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors Drug Discovery Today 2009, 14, 291-297
3. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
4. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315
5. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 2010, 10, 130-137
6. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance J. Med. Chem. 2010, 53, 1413-1437
7. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351, 95-105
8. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
9. Brylinski, M.; Skolnick, J. Comprehensive Structural and Functional Characterization of the Human Kinome by Protein Structure Modeling and Ligand Virtual Screening J. Chem. Inf. Model 2010, 50, 1839
10. Goldstein, D. M.; Gray, N. S.; Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discovery 2008, 7, 391-397
11. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
12. Fedorov, O.; Marsden, B.; Pogacic, V.; Rellos, P.; Müller, S.; Bullock, A. N.; Schwaller, J.; Sundström, M.; Knapp, S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20523-20528
13. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
14. Library of Integrated Network-based Cellular Signatures (LINCS). http://lincsproject.org/ (accessed Nov 30, 2012).
15. HMS LINCS DataBase. http://lincs.hms.harvard.edu/db/ (accessed Nov 30, 2012).
16. LINCS Information FramEwork (LIFE). http://lifekb.org/ (accessed Nov 30, 2012).
17. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Kinomics: characterizing the therapeutically validated kinase space Drug Discovery Today 2005, 10, 839-846
18. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery J. Med. Chem. 2008, 51, 7898-7914
19. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets Biochim. Biophys. Acta 2004, 1697, 243-257
20. Posy, S. L.; Hermsmeier, M. A.; Vaccaro, W.; Ott, K. H.; Todderud, G.; Lippy, J. S.; Trainor, G. L.; Loughney, D. A.; Johnson, S. R. Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening J. Med. Chem. 2011, 54, 54-66
21. Manallack, D. T.; Pitt, W. R.; Gancia, E.; Montana, J. G.; Livingstone, D. J.; Ford, M. G.; Whitley, D. C. Selecting screening candidates for kinase and G protein-coupled receptor targets using neural networks J. Chem. Inf. Comput. Sci. 2002, 42, 1256-1262
22. Xia, X.; Maliski, E. G.; Gallant, P.; Rogers, D. Classification of kinase inhibitors using a Bayesian model J. Med. Chem. 2004, 47, 4463-4470
23. Briem, H.; Gunther, J. Classifying "kinase inhibitor-likeness" by using machine-learning methods Chembiochem 2005, 6, 558-566
24. Sutherland, J. J.; Higgs, R. E.; Watson, I.; Vieth, M. Chemical Fragments as Foundations for Understanding Target Space and Activity Prediction J. Med. Chem. 2008, 51, 2689-2700
25. Aronov, A. M.; McClain, B.; Moody, C. S.; Murcko, M. A. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology J. Med. Chem. 2008, 51, 1214-1222
26. Kinase Knowledge Base (Q4 2009). http://eidogen-sertanty.com/kinasekb.php (accessed Nov 30, 2012).
27. Pipeline Pilot 8.0, version 8.0; Accelrys: San Diego, CA, 2010.
28. Glick, M.; Jenkins, J. L.; Nettles, J. H.; Hitchings, H.; Davies, J. W. Enrichment of high-throughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and Laplacian-modified naive Bayesian classifiers J. Chem. Inf. Model. 2006, 46, 193-200
29. Cramer, R. D., III Partial Least Squares (PLS): Its strengths and limitations Perspect. Drug Discovery Des. 1993, 1, 269-278
30. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures Org. Biomol. Chem. 2004, 2, 3256-3266
31. Rogers, D.; Brown, R. D.; Hahn, M. Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up J. Biomol. Screen. 2005, 10, 682-686
32. Sastry, M.; Lowrie, J. F.; Dixon, S. L.; Sherman, W. Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments J. Chem. Inf. Model. 2010, 50, 771-784
33. Rogers, D.; Hahn, M. Extended-Connectivity Fingerprints Chem. Inf. Model 2010, 50, 742-754
34. Li, Q.; Cheng, T.; Wang, Y.; Bryant, S. H. PubChem as a public resource for drug discovery Drug Discovery Today 2010, 15, 1052-1057
35. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364